AbbVie Inc. is aiming for research and development (R&D) to cure a rare disease that is considered life-threatening like Human Immuno-deficiency Virus (HIV), cancer, psoriasis, hepatitis, Parkinson’s, and renal diseases.
The drugmaker titan relies on their generated revenue on its flagship drug, Humira, designated for treating rheumatoid arthritis, along with multiple therapeutic segments. About $14 billion was generated from the product last year, and fueled 61% of the total sale of the company. Meanwhile, the drug posted a 12% growth this year, compared to 2014.
Subsequently, Humira’s portfolio that covers multiple segments like dermatology and gastroenterology is expanding evenly. AbbVie aims at expanding its indicated drugs across the new geographical markets in countries like China and Japan in order to visibly moved the effect of the patent expiration. Thus, it is likely that the drugmaker will attract more sales in the next years.
In order to surpass the major side effect of the patent expiration of Humira in the US, AbbVie remained working religiously for the recent drug portfolio to expand, and making it more actively competitive.
Imbruvica was acquired by the AbbVie Inc. from Pharmacyclics last year worth $21 billion. The BTK inhibitor made the drug. The company remained confident that the drug will settle about $7 billion on an annual basis, and is anticipated to hit $12, fueled by the increasing sale of Johnson and Johnson.
Furthermore, the drug is indicated for patients struggling from chronic lymphocytic leukemia, including patients suffering from Waldenströms macroglobulinemia. Thus, the drug was exposed to multiple phases of clinical examination in order to prove its efficacy in a diverse therapeutic areas.
The drug is potentially considered to generate revenue reaching $1,811 million this year, citing the small molecule to be the second-biggest drug of the pharmaceutical firm after Humira. Its figure is anticipated to settle for $3,877 million by 2020, along with a 43.8% Compound Annual Growth Rate.
Apparently, the treatment for the small lymphocytic leukemia was given a green signal by the Food and Drug Administration, with or without the removal of chromosome 17p. The said approval was based on the supplemental New Drug Application review given November last year.
The Committee of the European Medicine Agency for Medicinal Products for Human Use has confirmed an approval of Imbruvica in the European Union in April 2016, categorized for adult patients with previously-untreated chronic lymphocytic leukemia.
Hence, it suggests that if the drug is given a green signal by the European Commission, it indicated that it is the fifth time that Imbruvica attained approval for CLL. The drug has already been approved for Lymphoma, Mantle-Cell, Leukemia, and SLL.